GREEN TEA WITH HIGH-DENSITY CATECHINS IMPROVES LIVER FUNCTION AND FAT INFILTRATION IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS
含有高密度儿茶素的绿茶可改善非酒精性脂肪肝患者的肝功能和脂肪浸润
基本信息
- 批准号:16590651
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2004
- 资助国家:日本
- 起止时间:2004 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
BACKGROUND/AIM : Non-alcoholic fatty liver disease (NAFLD) is a common disease in developed countries. Numerous approaches have been used to study NAFLD in patients based on the risk of progression to severe liver disease. Catechins, a major component of green tea extract, have the effects of body-fat reduction and antihyperlipidemia. Therefore, we evaluated the efficacy of green tea with high-density catechins for NAFLD patients.METHODS : Fourteen patients (5 males and 9 females, mean age 55.9±14.2 years) with NAFLD were randomized to receive either green tea with high-density catechins (catechins 1080 mg/day) or placebo (catechins less than 200mg/day) for 12 weeks in a randomized, double-blind study. Ultrasonography and computed tomography (CT) were performed at baseline and at 12 weeks. Fatty infiltration of the liver was evaluated by CT using corrected liver attenuation. Serum chemistry values were monitored at baseline and at 12 weeks. Urine 8-isoprostane, a marker of oxidant inju … More ry in vivo, was monitored at the same time. The effects for an individual patient were evaluated by the ratio (improvement rate) of each data point at baseline and at 12 weeks.RESULTS : In the high-density catechins group, body mass index did not change significantly between baseline and 12 weeks (27.8±4.4 vs. 26.9±4.5, respectively). Compared to baseline, serum alanine aminotransferase decreased to 68.5±18.9% (p<0.01) at 12 weeks in the high-density catechins group while remaining unchanged in the placebo group (92.8±13.0%, NS ; p<0.05 between groups). Liver CT attenuation was significantly improved at 12 weeks compared to baseline in all patients of the high-density catechins group, and a significant difference in liver CT attenuation improvement rate was recognized between the high-density catechins and placebo groups (11.2±3.0% vs.-5.3±11.0%, p<0.01). Urine 8-isoprostane decreased to 76.5±16.4%(p<0.01) at 12 weeks in the high-density catechins group while remaining unchanged in the placebo group (102.4±22.8%, NS ; p<0.05 between groups).CONCLUSIONS : Green tea with high-density catechins caused a reduction of inflammation and fatty accumulation in the liver of NAFLD patients. In addition, green tea with high-density catechins decreased the oxidative stress that plays an integral part in the development of NAFLD, and may be useful for treatment of NAFLD patients. Less
背景/目的:非酒精性脂肪性肝病(NAFLD)是发达国家的常见病。基于进展为严重肝病的风险,已经使用了许多方法来研究患者的NAFLD。儿茶素是绿色茶提取物的主要成分,具有降脂、降血脂的作用。因此,我们评估了绿色茶与高密度儿茶素对NAFLD patients.METHODS的疗效:14例NAFLD患者(5男9女,平均年龄55.9±14.2岁)随机接受绿色茶与高密度儿茶素(儿茶素1080毫克/天)或安慰剂(儿茶素低于200毫克/天)12周的随机,双盲研究。在基线和12周时进行超声检查和计算机断层扫描(CT)。使用校正的肝脏衰减通过CT评估肝脏的脂肪浸润。在基线和12周时监测血清化学值。尿8-异前列腺素是氧化损伤的标志物 ...更多信息 在体内,同时监测。对个别患者的影响进行了评估的比率(改善率)的每个数据点在基线和在12 weeks.Results:在高密度儿茶素组,体重指数没有改变之间的基线和12周(27.8±4.4与26.9±4.5,分别)显着。与基线相比,高密度儿茶素组的血清丙氨酸氨基转移酶在12周时下降至68.5±18.9%(p<0.01),而安慰剂组保持不变(92.8± 13.0%,NS ;组间p<0.05)。与基线相比,高密度儿茶素组的所有患者的肝脏CT衰减在12周时显著改善,并且在高密度儿茶素组和安慰剂组之间认识到肝脏CT衰减改善率的显著差异(11.2±3.0% vs.- 5.3± 11.0%,p<0.01)。在12周时,高密度儿茶素组的尿8-异前列烷降低至76.5±16.4%(p<0.01),而安慰剂组保持不变(102.4± 22.8%,NS ;组间p<0.05)。此外,含有高密度儿茶素的绿色茶降低了在NAFLD发展中起重要作用的氧化应激,可能对治疗NAFLD患者有用。少
项目成果
期刊论文数量(32)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hepatic stellate cell and liver fibrosis
肝星状细胞与肝纤维化
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Masaru Harada;et al.;Kawaguchi T et al.;Ryuichiro Sakata et al.
- 通讯作者:Ryuichiro Sakata et al.
Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90.
- DOI:10.1016/s0168-8278(03)00477-x
- 发表时间:2004
- 期刊:
- 影响因子:25.7
- 作者:R. Sakata;T. Ueno;Toru Nakamura;M. Sakamoto;T. Torimura;M. Sata
- 通讯作者:R. Sakata;T. Ueno;Toru Nakamura;M. Sakamoto;T. Torimura;M. Sata
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SAKATA Ryuichiro其他文献
SAKATA Ryuichiro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SAKATA Ryuichiro', 18)}}的其他基金
Green tea polyphenol (-)-epigallocatechin-3 gallate inhibits PDGF-induced proliferation of human hepatic stellate cell
绿茶多酚(-)-表没食子儿茶素-3没食子酸酯抑制PDGF诱导的人肝星状细胞增殖
- 批准号:
13670575 - 财政年份:2001
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
GPR35:作为非酒精性脂肪肝疾病潜在治疗策略的作用和激动机制
- 批准号:
MR/X008827/1 - 财政年份:2024
- 资助金额:
$ 2.24万 - 项目类别:
Research Grant
AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients (Artemis)
加速虚拟双胞胎向脂肪肝患者个性化管理的转化(Artemis)
- 批准号:
10109933 - 财政年份:2024
- 资助金额:
$ 2.24万 - 项目类别:
EU-Funded
Perfluoroalkyl substances and non-alcoholic fatty liver disease in children: Leveraging magnetic resonance imaging to unravel potential mechanisms and exposure mixture effects
全氟烷基物质与儿童非酒精性脂肪肝:利用磁共振成像揭示潜在机制和暴露混合物效应
- 批准号:
10646759 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
An NADH-ChREBP axis in fatty liver disease and dyslipidemia
脂肪肝疾病和血脂异常中的 NADH-ChREBP 轴
- 批准号:
10564369 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Development of Early Diagnostic Markers for Non-Alcoholic Fatty Liver Disease (NAFLD) and Investigation of Inflammatory Mechanisms of NAFLD
非酒精性脂肪性肝病(NAFLD)早期诊断标志物的开发及NAFLD炎症机制的研究
- 批准号:
23K07466 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Tackling the fatty liver by targeting the gut
通过针对肠道来解决脂肪肝
- 批准号:
2869577 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Studentship
Interaction between Genome and Heavy Metals in Nonalcoholic Fatty Liver Disease
非酒精性脂肪肝中基因组与重金属的相互作用
- 批准号:
10658148 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
AAV mediated gene knockdown of PIK3C2B as a therapeutic strategy for X-linked myotubular myopathy and fatty liver disease
AAV 介导的 PIK3C2B 基因敲低作为 X 连锁肌管肌病和脂肪肝的治疗策略
- 批准号:
10753786 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Bacteriotherapy to treat non-alcoholic fatty liver disease
细菌疗法治疗非酒精性脂肪肝
- 批准号:
2893992 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Studentship
The Gut-Liver Axis in HIV-Related Non-Alcoholic Fatty Liver Disease
HIV 相关非酒精性脂肪肝中的肠肝轴
- 批准号:
10762284 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别: